Janux Therapeutics, Inc. (JANX) stock

JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3031% below fair value

$11.37−0.13 (-1.09%)

Close on Nov 13, 2026Market cap $695.13MP/E –Yield –

Janux Therapeutics statistics

74 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: Feb 25, 2027 (estimated, during market hours)
Last ex-dividend date: No dividends
Fundamentals through: Sep 30, 2026
Share price as of: Nov 13, 2026

Valuation ratiosIndustry

Market Cap: $695.13M; $272.32M
Enterprise Value: -$250.59M; $146.23M
PS Ratio: 29.85; 3.66
PB Ratio: 0.76; 2.00
P/TBV Ratio: 0.76; 2.22

Enterprise valuationIndustry

EV / Sales: -10.76; 2.57

Share statisticsIndustry

Shares Outstanding: 61M; 58M
Shares Change (YoY): 3.41%; 10.8%
Shares Change (QoQ): 0.16%; 0.50%
Float: 48M; 49M
Shares Held by Insiders: 21.3%; 11.7%
Shares Held by Institutions: 100.8%; 56.4%

Short sellingIndustry

Short Interest: 5M; –
Short Interest Change: 0.05%; -0.80%
Short % of Float: 11.1%; 9.01%
Short % of Shares Outstanding: 8.72%; 6.30%
Days to Cover: 7.98; 5.15

Stock price statisticsIndustry

52-Week High: $35.34; –
52-Week Low: $11.15; –
20-Day Moving Average: $15.95; –
50-Day Moving Average: $16.80; –
200-Day Moving Average: $15.36; –
Average True Range (14): $1.18; –
Price Change (1 Week): -35.5%; -1.15%
Price Change (1 Month): -34.4%; -4.87%
Price Change (3 Months): -30.1%; -21.0%
Price Change (6 Months): -18.1%; -20.6%
Price Change (YTD): -17.6%; -23.6%
Price Change (1 Year): -60.1%; -22.4%
Price Change (3 Years): 36.5%; -29.5%
Price Change (5 Years): -49.4%; -77.9%
Average Volume (10 Days): 1M; –
Average Volume (20 Days): 1M; –
Average Volume (90 Days): 886,532; –
Relative Volume: 0.81; 0.70
Relative Strength Index (14): 28.9; 43.4
Volatility (1 Year): 77.5%; 80.1%
Beta (5 Years): 1.60; 1.07

MarginsIndustry

Operating Margin: -599.3%; -38.7%
Profit Margin: -428.7%; -31.6%
EBITDA Margin: -599.3%; -27.7%
FCF Margin: -232.6%; -9.56%

Returns on capitalIndustry

Return on Equity (ROE): -10.6%; -49.9%
Return on Assets (ROA): -9.94%; -40.6%
Return on Capital Employed (ROCE): -15.0%; -37.9%

Financial positionIndustry

Current Ratio: 17.69; 3.30
Quick Ratio: 17.44; 2.39

GrowthIndustry

Revenue Growth (YoY): 132.9%; 6.82%
Revenue Growth (3Y CAGR): 5.11%; 2.25%

EfficiencyIndustry

Asset Turnover: 0.02; 0.40
Revenue Per Employee: $213.66K; $429.29K
Profits Per Employee: -$916.05K; -$689.41K
Employee Count: 109; 74
WACC: 13.1%; 10.2%

Income statement (TTM)Industry

Revenue: $23.29M; $66.37M
Operating Income: -$139.56M; -$21.37M
Net Income: -$99.85M; -$22.35M
EBITDA: -$139.56M; -$17.21M
EPS (Diluted): -$1.59; -$0.76

Balance sheetIndustry

Cash & Short-Term Investments: $945.72M; $68.68M
Net Cash (Debt): $945.72M; $17.76M
Net Cash Per Share: $15.47; $0.80
Equity (Book Value): $911.61M; $53.89M
Book Value Per Share: $14.91; $1.50
Tangible Book Value: $911.61M; $27.13M
Working Capital: $905.14M; $79.99M

Cash flow (TTM)Industry

Operating Cash Flow: -$53.58M; -$12.38M
Capital Expenditures: -$583.00K; -$1.00M
Free Cash Flow: -$54.16M; -$18.21M
FCF Per Share: -$0.89; -$0.42

Dividends and yieldsIndustry

Earnings Yield: -14.4%; -21.8%
FCF Yield: -7.79%; -9.44%

Scores and fair valueIndustry

Altman Z-Score: 5.85; 0.23
Piotroski F-Score: 2; 4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

Period	JANX	S&P 500	Difference	JANX per year	S&P 500 per year
1 month	-33.8%	-3.0%	−30.8 pts
3 months	-28.9%	-2.8%	−26.2 pts
Year to date	-17.6%	+11.5%	−29.1 pts
1 year	-58.6%	+13.5%	−72.1 pts
3 years	+60.4%	+77.7%	−17.3 pts	+17.0%	+21.1%
5 years	-49.4%	+72.6%	−122.0 pts	-12.7%	+11.5%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

5M JANX shares were sold short on Oct 30, 2026, up 0.1% from the previous report, or 11.08% of the shares available to trade. At recent volumes it would take 8.0 days to buy them back. Over the last 20 sessions, 38.1% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	5,329,932	+0.1%	667,598	8.0
Oct 15, 2026	5,327,163	-6.3%	859,874	6.2
Sep 30, 2026	5,684,346	-3.5%	969,533	5.9
Sep 15, 2026	5,891,965	-2.8%	999,885	5.9
Aug 31, 2026	6,063,535	-8.5%	776,426	7.8
Aug 14, 2026	6,626,696	+11.9%	607,942	10.9
Jul 31, 2026	5,922,899	-8.2%	765,256	7.7
Jul 15, 2026	6,454,019	-9.2%	1,003,518	6.4
Jun 30, 2026	7,108,085	-6.7%	1,978,810	3.6
Jun 15, 2026	7,615,380	-5.9%	694,792	11.0
May 29, 2026	8,091,847	+3.4%	1,184,704	6.8
May 15, 2026	7,827,096	-1.3%	810,461	9.7

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in Janux Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is JANX.

Compare: JANX vs CTMX · JANX vs PRLD · JANX vs PYXS · JANX vs CUE · JANX vs CBIO

Revenue growth132.9% · median 220.3%

Operating margin-599.3% · median -488.5%

Net margin-428.7% · median -522.4%

Company	Revenue	Growth
CUE	$37.65M	+354.4%
JANX	$23.29M	+132.9%
PRLD	$22.42M	+220.3%
CBIO	$15.00M	–
CTMX	$14.03M	-87.7%
PYXS	–	–

Company

Next earnings (est.): Feb 25, 2027, during market hours
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 109
Held by institutions: 100.0%
Auditor: Ernst & Young LLP
SEC CIK: 1817713

Advertisement
300 × 250

See a number that looks wrong?